Key result
Elevated baseline D-dimer levels (≥500 ng/mL) independently predicted shorter survival in patients with sarcoma (HR 4.24; 95% CI 1.88-9.60).
Cohort (n=45)
Hazard Ratio: 4.24 (95% CI 1.88–9.6)
p-value: p=0.015
No takes yet. Share an insight, caveat, or question.
May support sarcoma risk stratification; hypothesis-generating and requires prospective validation before clinical use.
Raj et al. (2011) conducted a cohort in Sarcoma (n=45). Elevated D-dimer levels (≥500 ng/mL) vs. D-dimer <500 ng/mL was evaluated on Survival (HR 4.24, 95% CI 1.88-9.60, p=0.015). Elevated baseline D-dimer levels (≥500 ng/mL) independently predicted shorter survival in patients with sarcoma (HR 4.24; 95% CI 1.88-9.60).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: